This article is mentioned in:

Introduction

Intestinal ischemia and reperfusion (II/R) is encountered under various clinical conditions, and contributes to multi-organ failure and high levels of mortality (60–80%) (1–3). II/R not only induces intestinal damage, but also affects remote organs, including the lungs, leading to acute lung injury (ALI) and acute respiratory distress syndrome in patients (4,5). II/R-induced ALI is caused by an excessive systemic inflammatory response, which is triggered by the release of proinflammatory cytokines and bacteria-derived endotoxins from the reperfused ischemic gut tissue (6–8). In addition, animal models and clinical data support the concept that excessive elevation of proinflammatory cytokines is a major contributor in remote organ injury following II/R (9–11).

Among the numerous proinflammatory cytokines, tumor necrosis factor-α (TNF-α) has a critical role in the occurrence and development of ALI caused by II/R (12,13). Preclinical and clinical studies have reported that suppressing the expression of TNF-α may reduce the progression of inflammation in numerous diseases, including Crohn's disease (14–16). Using an anti-TNF antibody, Caty et al revealed that blocking TNF ameliorates pulmonary microvascular permeability (13). In addition, Sorkine et al demonstrated that soluble TNF-α receptors have the ability to reduce bowel ischemia-induced lung permeability and neutrophil sequestration (17). These results suggest that TNF-α may serve major roles in the lung injury induced by II/R. However, pharmacological treatment options for ALI following II/R are limited, with most targeting proinflammatory cytokines and oxidative stress pathways (18). Therefore, there is an urgent requirement to identify an effective approach for ALI treatment.

Downregulation of mRNA transcripts by RNA interference (RNAi) and small interfering (si)RNA (19) has been adopted as an invaluable research tool, which holds promise as a novel strategy for drug development (14), via the suppression of targeted gene expression (20). As a therapeutic method, the RNAi approach is safe and has incomparable long-term effects.

It has been hypothesized that blocking expression of the proinflammatory cytokine TNF-α may protect the lungs from remote organ injury following II/R. Therefore, the present study employed a rat model of II/R injury and used short hairpin (sh)RNA technology to examine the efficacy of TNF-α knockdown on II/R-induced ALI, and to investigate its association with interleukin-10 (IL-10) expression in lung tissues.

Materials and methods

Animals and grouping

Adult male Sprague-Dawley rats (8–12 weeks old), weighing 230–280 g, were obtained from the Experimental Animal Center of Sichuan University (Chengdu, China). Guide lines for Laboratory Animal Care and Safety from the National Institutes of Health (Bethesda, MD, USA) were followed. The rats were maintained in plastic cages (2 rats/cage) with soft bedding, and were given free access to food and water. Rats were maintained under the following conditions: Controlled room temperature, 22–25°C humidity, 45–50%; 12-h light/dark cycle. Animal care and all experimental protocols were approved by the Institutional Medical Experimental Animal Care Committee of Kunming Medical University (Kunming, China).

A total of 152 rats were randomly divided into the following two groups, as described in Table I: i) Sham and ii) II/R (8, 16 and 24 h). In the II/R group, rats underwent II/R injury via occlusion of the superior mesenteric artery (SMA) and coeliac artery (CA) for 40 min, and subsequent reperfusion for 8, 16 or 24 h. In addition, the II/R group was subdivided into the negative control (II/R + Lv-NC vector) and TNF-α shRNA groups (II/R + RSH054951-5-HIVmU6), as described in Table II. Rats in the negative control group were injected with the Lv-NC vector, whereas rats in the TNF-α shRNA group were injected with the TNF-α shRNA lentivirus.

Table I Animal model and number of rats distribution.

Table I

Animal model and number of rats distribution.

Group	Model	Lung edema	H&E	IF	qPCR/WB
Sham	Sham	8	6	6	8
8 h	II/R	8	6	6	8
16 h	II/R	8	6	6	8
24 h	II/R	8	6	6	8

[i] H&E, hematoxylin and eosin; IF, immunofluorescence; II/R, intestinal ischemia and reperfusion; qPCR, quantitative polymerase chain reaction; WB, western blotting.

Table II Animal grouping and and number of rats distribution.

Table II

Animal grouping and and number of rats distribution.

Group	Model (24 h)	H&E	qPCR/WB	IF
Control	II/R+Lv-NC vector	6	8	6
TNF-α shRNA	II/R+RSH054951-5-HIVmU6	6	8	6

[i] H&E, hematoxylin and eosin; IF, immunofluorescence; qPCR, quantitative polymerase chain reaction; shRNA, short hairpin RNA: TNF-α, tumor necrosis factor-α; WB, western blotting.

Production of lentivirus TNF-α shRNA plasmid

To investigate the function of TNF-α in rat lungs following II/R, human immunodeficiency virus (HIV)-based vectors were used. TNF-α gene information was gathered from the National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/nuccore/NM_012675.3). One potential shRNA sequence targeting TNF-α mRNA (gcccgtagcccacgtcgta) was used to silence TNF-α expression (called RSH054951-5-HIVmU6; provided by GeneCopoeia, Inc., Rockville, MD, USA), whereas one non-sense shRNA sequence was used as a negative control; sequences were designed and purchased from GeneCopoeia, Inc.

RNA knockdown efficiency screening

In order to screen the efficiency of the potential TNF-α shRNA sequence, PC12 cells, purchased from the Animal Research Institute of the Chinese Academy of Medical Sciences (Beijing, China), were seeded in 6-well plates and incubated at 37°C in an atmosphere containing 5% CO2, prior to transfection with shRNA sequences. Brie fly, cultured PC12 cells (1×105/ml), were transfected at 4°C with a mixture including 1 μg shRNA fragment and 3 μl transfection reagents (SuperFectin™ II; Shanghai Pufei Biological Technology Co., Ltd., Shanghai, China) according to the manufacturer's protocol. A total of 12 h post-transfection, basal culture medium was replaced with Dulbecco's modified Eagle's medium (DMEM; HyClone; GE Healthcare, Logan, UT, USA) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and penicillin-streptomycin solution (50 U/ml; HyClone; GE Healthcare). Subsequently, total RNA was extracted from PC12 cells 48 h post-transfection and the effects of shRNA on TNF-α mRNA expression were examined using quantitative polymerase chain reaction (qPCR) (21). The protein expression levels were evaluated by western blotting.

Recombinant lentiviral vector production

Lentiviral vector production was conducted according to the manufacturer's protocol of the Lenti-Pac™ HIV Expression Packaging kit (GeneCopoeia, Inc.). Briefly, 293Tα lentiviral packaging cells (GeneCopoeia, Inc.) were cultured in DMEM supplemented with 10% heat-inactivated FBS at 37°C in an atmosphere containing 5% CO2. Cell confluence between 70 and 80% was optimal for transfection. Lentiviral expression plasmid (1.25 μg) was mixed with 2.5 μl (0.5 μg/μl) packing mix (Lenti-Pac HIV) and the mixture was added to 75 μl Opti-MEM® I (Gibco; Thermo Fisher Scientific, Inc.). Diluted EndoFectin Lenti was also added to the vector mixture. Following incubation at room temperature for 25 min, the mixtures were added to the culture medium of 293Tα cells. Subsequently, 8 h post-transfection, the culture medium was replaced with heated DMEM containing 10% FBS. Furthermore, Titer Boost reagent (10 μl; GeneCopoeia, Inc.) was added to improve virus generation. Transfection efficiency was confirmed by the detection of mCherryFP, which was fused to the plasmid vector, under a fluorescence microscope. A total of 72 h post-transfection, cells were stimulated, the culture medium was collected and centrifuged at 3,600 × g for 10 min at 4°C, and the supernatant was filtered. Lentiviral stocks were aliquoted and stored at −80°C until further use (21).

II/R model and lentivirus injection

Rats were fasted with no restriction of water access for 24 h prior to surgery. II/R was induced by SMA and CA occlusion, as described previously (22). Briefly, the rats were anesthetized intraperitoneally (i.p.) with ketamine-xylazine (100 and 20 mg/kg i.p., respectively) and placed in a supine position. The SMA and CA were exposed and isolated through a midline laparotomy and clamped with an atraumatic microvascular clip for 40 min. After 40 min ischemia, the artery clamps were removed and intestinal perfusion was re-established. Sham animals underwent the same surgical procedure without artery clamping.

For TNF-α interference, the previously described lentiviruses were injected through the diaphragm into the right lung tissue (5 μl/2×108/ml). After 3 min, the needle tip was pulled out and the diaphragm was sutured. The arteries were clamped following lentiviral injection. After 40 min of ischemia, the SMA and CA were loosened and the skin was sutured, after which 0.5 ml normal saline was injected into the enterocoelia. Rats in the negative control group were injected with Lv-NC.

Tissue harvest

At the end of reperfusion (8, 16 and 24 h), experimental and sham rats were anaesthetized with ketamine-xylazine (100 and 20 mg/kg i.p., respectively) and euthanized with pentobarbital sodium (200mg/kg i.p.). Subsequently, lung tissues from rats in each group were collected and analyzed.

Lung edema determination

Lung edema was estimated by comparing the lung wet/dry weight ratio. At the end of the experiments, lungs were immediately removed and weighed to obtain the wet weight. The tissues were then dried in an oven at 90°Cfor 24 h and were weighed again to obtain the dry weight. Lung wet/dry weight ratio was calculated as previously described (23).

Histological analysis

Histological analysis of the lungs was performed by hematoxylin and eosin (H&E) staining. Briefly, tissue samples were fixed in 10% (v/v) formalin in neutral-buffered solution for 72 h at room temprature, and the fixed tissues were embedded in paraffin. Subsequently, tissue blocks were cut into 5-μm sections, transferred to glass slides and stained with hematoxylin for 7 min, and eosin for 15 sec respectively, at room temprature. Finally, these sections were observed under a light microscope to detect morphological alterations. Lung injury was scored as previously described (24).

Reverse transcription (RT)-qPCR

The mRNA expression levels of TNF-α and IL-10 were detected using RT-qPCR. Briefly, total RNA was isolated from the lung tissues using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. RNA was reverse transcribed to cDNA using the RevertAid™ First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. qPCR was then performed to determine the expression levels of target genes. The primers and TaqMan probes were designed with Primer Premier 5.0 (Premier Biosoft International, Palo Alto, CA, USA). The primer sequences were as follows (5′-3′): TNF-α, forward GCCCACGTCGTAGCAA, reverse, GTCTTTGAGATCCATGCCAT (annealing temperature, 52°C); IL-10, forward CAGAAATCAAGGAGCATTTG, reverse CTGCTCCACTGCCTTGCTTT (annealing temperature, 50°C); and β-actin, forward GAAGATCAAGATCATTGCTCCT and reverse TACTCCTGCTTGCTGATCCA (annealing temperature, 52°C). The rat β-actin housekeeping gene was used as an internal control. The qPCR reactive system was established as follows: 2X PCR, Master Mix (12.5 μl), PCR water nuclear-free (10.5 μl), forward primer (0.5 μl), reverse prime (0.5 μl), cDNA template (1 μl); total, 25 μl; 1 μl water was added as a negative control instead of cDNA. Amplification was conducted using an ABI 7300 PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.), under the following conditions: Initial denaturation for 1 cycle at 95°C for 2 min, followed by denaturation at 95°C for 15 sec, and amplification at 53°C for 20 sec and followed by extension at 60°C for 30 sec for a total of 40 cycles. The quantification cycle (Cq) of each sample was recorded as a quantitative measure of the amount of PCR product in the sample. Finally, the relative mRNA expression levels of the target genes were calculated following normalization to β-actin mRNA using the 2−ΔΔCq method (25).

Immunofluorescence (IF) staining

A total of 8, 16 and 24 h following reperfusion, paraffin-embedded lung sections underwent IF staining of TNF-α and IL-10. Following routine de-paraffinization and rehydration, tissue sections were incubated with PBS containing 3% goat serum (Sigma, St. Louis, MO, USA) for 30 min at 37°C, and were then incubated overnight at 4°C with TNF-α (1:500, rabbit) and IL-10 (1:100, rabbit; catalog no. Ab9969) primary antibodies (both from Abcam, Cambridge, UK) which were diluted in PBS containing 2% normal goat serum. A negative control was performed by adding PBS instead of the primary antibody. Subsequently, sections were washed three times with PBS and were incubated with Cy3 fluorescence-labeled secondary antibody (1:200, anti-rabbit; catalog no. 111-165-003; Jackson Laboratory, Bar Harbor, ME, USA), in the dark for 30 min at 37°C. Sections were then washed three times with PBS, mounted onto gelatin-coated glass microscope slides, air dried and cover-slipped in a glycerol-based mounting medium. Cell nuclei were visualized by DAPI-Fluoromount (Beyotime Institute of Biotechnology, Shanghai, China). Photomicrographs were captured under a fluorescence microscope (Leica Microsystems GmbH, Wetzlar, Germany).

Western blotting

Tissue samples were lysed and homogenized in 50 ml radioimmunoprecipitation acid lysis buffer (Beyotime Institute of Biotechnology) containing a 2% protease inhibitor cocktail tablet (Roche Diagnostics GmbH, Mannheim, Germany). Subsequently, a Bicinchoninic Acid protein assay kit (Beyotime Institute of Biotechnology) was used to detect the protein concentration and, 100 μg total protein was then resolved by 15% SDS-PAGE in electrophoresis buffer (24.8 mM Tris, 192 mM glycine and 0.1% SDS) at 60 V for 30 min, and 100 V for 1.5 h. The precipitated proteins were then transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA) at 350 mA for 4 h, using transfer buffer: 24.8 mM Tris, 192 mM glycine and 10% methanol. The membranes were blocked with Tris-buffered saline with 1/1,000 Tween (TBST) containing 5% non-fat milk for 1 h at room temperature. Subsequently, the membranes were incubated with TNF-α primary antibody (1:5,000, rabbit anti-rat; ab9755; Abcam) in TBS overnight at 4°C; β-actin (1:1,000; catalog no. ABM40028; Abcam) was used as an internal control. Following incubation with the primary antibodies, membranes were repeatedly rinsed in TBST four times prior to incubation for 1.5 h with a secondary antibody at room temprature (goat anti-rabbit immunoglobulin G; 1:5,000; catalog no. ab6721; Abcam). Finally, the membranes were rinsed four times in TBST and detected using ChemiDoc XRS System with Image Lab Software 2.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using an Enhanced Chemiluminescence reagent (catalog no. BL520A; Bio-Rad Laboratories, Inc.).

Statistical analysis

Statistical analysis was conducted using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA) and the experiments were repeated 3 times. Data are presented as the means ± standard deviation and were subjected to statistical analysis using one-way analysis of variance (ANOVA) or Student's t-test. For multiple group comparisons, ANOVA with Tukey's post hoc multiple comparisons test was applied. P<0.05 was considered to indicate a statistically significant difference.

Results

Lung edema and morphology

Compared with in the sham group, the lung wet/dry weight ratio of the II/R group was significantly increased 8, 16 and 24 h after reperfusion; the results indicated that pulmonary edema was aggravated as the time interval lengthened (P<0.05; Fig. 1A). As shown in Fig. 1B, lung tissue sections were stained with H&E and observed under a light microscope; alveolar structure in the sham group was ordered, and no congestion, neutrophil invasion or interstitial edema was detected. However, in the II/R group, the alveolar structure was disordered and integrity of the alveolar wall was damaged, which was accompanied by a thickened alveolar wall and edema. In addition, neutrophils accumulated in the alveolar space, alveolar capillary congestion and exudation occurred, part of the alveolus pulmonis collapsed, and there was hemorrhaging in the alveolar space. Based on these observations, lung injury scores were significantly increased in the II/R group compared with in the sham group 8, 16 and 24 h post-reperfusion (P<0.05; Fig. 1C).

Figure 1 Lung edema and morphological damage are induced by II/R. (A) Lung edema was analyzed by lung wet/dry weight ratio in the sham and II/R groups (8, 16 and 24 h after reperfusion). Data are presented as the means ± standard deviation (n=8). *P<0.05 compared with the sham group. (B) Morphological alterations in the lung tissue of the sham and II/R groups (8, 16 and 24 h) were observed under a light microscope. Disordered alveolar structure, congestion, neutrophil invasion and interstitial edema were observed in the lungs of the II/R group (8, 16 and 24 h). Scale bar, 20 μm. (C) Lung injury scores in the sham and II/R groups. Data are presented as the means ± standard deviation (n=6). *P<0.05 compared with the sham group. II/R, intestinal ischemia and reperfusion.

Expression levels of TNF-α in lung tissues

Between 8 and 24 h post-reperfusion, the mRNA and protein expression levels of TNF-α in the II/R group exhibited an increasing trend compared with in the sham group (P<0.05; Fig. 2A and B). In addition, IF labeling of TNF-α, which exhibited red fluorescence, indicated that weak TNF-α immunostaining was detected in the lung tissues of the sham group, whereas strong immunostaining was detected in the lung tissues of the II/R group 8, 16 and 24 h post-reperfusion. In particular, TNF-α immunostaining was diffuse and intense 24 h following reperfusion (Fig. 2C).

Figure 2 Expression levels of TNF-α in lung tissues. (A) mRNA expression levels of TNF-α were detected in lung tissues by quantitative polymerase chain reaction. Data are presented as the means ± standard deviation (n=8). *P<0.05 compared with the sham group. (B) Protein expression levels of TNF-α were assessed by western blotting. Compared with in the sham group, TNF-α protein expression was increased in the lung tissue 8, 16 and 24 h post-reperfusion in the II/R group. Data are presented as the means ± standard deviation (n=8). *P<0.05 compared with the sham group. (C) Representative photomicrographs exhibiting immunostaining of TNF-α (red fluorescence) in lung cells from the sham and II/R groups (8, 16 and 24 h post-reperfusion). Immunofluorescence intensity was increased between the two groups; the 24 h post-reperfusion group possessed the strongest red staining. Blue fluorescence represented nuclei stained by DAPI. Scale bar, 25 μm. II/R, intestinal ischemia and reperfusion; OD, optical density; TNF-α, tumor necrosis factor-α.

Efficiency of TNF-α knockdown

Lentivirus-mediated TNF-α interference was used to knockdown the expression of TNF-α. The lentivirus-carried TNF-α shRNA sequence is presented in Fig. 3A. PC12 cells were subjected to shRNA transfection, in order to determine the interfering efficiency. Compared with in the control group, the mRNA and protein expression levels of TNF-α were reduced in the shRNA plasmid transfection groups (P<0.05), as determined by qPCR and western blotting (Fig. 3B and C). Subsequently, the shRNA sequence was inserted into a plasmid to produce a recombinant vector, after which recombinant vectors containing TNF-α shRNA and mCherryFP were transfected into 293Tα cells. IF detection confirmed that 293Tα cell emitted red fluorescence, indicating successful transfection (Fig. 3D). These findings confirmed that lentivirus-mediated TNF-α interference was successful, and with the addition of lentivirus, TNF-α was significantly inhibited.

Figure 3 Generation of a recombinant lentivirus targeting TNF-α. (A) TNF-α shRNA was inserted into a lentivirus plasmid; the sequence is stated. (B) mRNA expression levels of TNF-α were measured by quantitative polymerase chain reaction. (C) Protein expression levels of TNF-α were measured by western blotting. Data are presented as the means ± standard deviation. *P<0.05 compared with the control group (non-sense shRNA). (D) 293Tα cells were transfected with TNF-α shRNA lentivirus. Virus production carrying mCherryFP was visualized as red staining under a fluorescence microscope, indicating successful transfection. Scale bar, 25 μm. OD, optical density; shRNA, short hairpin RNA; TNF-α, tumor necrosis factor-α.

TNF-α knockdown ameliorates ALI following II/R

Following TNF-α inhibition, western blotting confirmed that the protein expression levels of TNF-α were significantly decreased in lung tissues (P<0.05; Fig. 4A). Furthermore, H&E staining indicated that inflammatory responses were improved, and lung injury scores were reduced 24 h after reperfusion in the TNF-α group compared with in the negative control group (P<0.05; Fig. 4B and C).

Figure 4 Alterations in lung injury following TNF-α interference. (A) Western blotting was used to detect TNF-α protein expression in lung tissues following TNF-α shRNA injection. Data are presented as the means ± standard deviation (n=8). *P<0.05 compared with the negative control group. (B) Hematoxylin and eosin staining of lung tissues from the negative control and TNF-α shRNA groups. The left image is the negative control group, and the right image is the TNF-α shRNA group. Scale bar, 20 μm. (C) Lung injury scores were improved in the TNF-α interference group 24 h post-reperfusion. Scores represent the average results of three blinded observers. Data are presented as the means ± standard deviation (n=6). *P<0.05 compared with the negative control group. II/R, intestinal ischemia and reperfusion; OD, optical density; shRNA, short hairpin RNA; TNF-α, tumor necrosis factor-α.

Knockdown of TNF-α upregulates the expression of IL-10

To determine the effects of TNF-α interference on the production of IL-10, the expression levels of IL-10 were detected in lung tissues. qPCR demonstrated that the mRNA expression levels of IL-10 were significantly increased in the TNF-α shRNA group compared with in the negative control group (P<0.05; Fig. 5A). Furthermore, immunostaining of IL-10 was stronger in the TNF-α shRNA group than in the negative control group (Fig. 5B).

Figure 5 Expression of IL-10 following TNF-α interference. (A) A total of 24 h post-reperfusion, quantitative polymerase chain reaction indicated that the mRNA expression levels of IL-10 were significantly increased following TNF-α knockdown. Data are presented as the means ± standard deviation (n=8). *P<0.05 compared with the negative control group. (B) Immunofluorescent staining of IL-10 in the lungs of the negative control and TNF-α shRNA groups. The left image is the negative control group, and the right image is the TNF-α shRNA group. Scale bar, 25 μm. IL-10, interleukin-10; shRNA, short hairpin RNA; TNF-α, tumor necrosis factor-α.

Discussion

The present study demonstrated that TNF-α knockdown may alleviate the inflammatory response associated with II/R-induced ALI by interfering with TNF-α expression and upregulating IL-10 in the lung tissues. These findings suggested that TNF-α RNA interference may be used as a strategy for the prevention or treatment of II/R-induced ALI in future clinical trials.

The present results indicated that II/R induced an acute inflammatory response in the lungs, in which adherence and infiltration of neutrophils was increased, and interstitial edema occurred; these observations were associated with worsened lung injury scores. These observations may significantly contribute to II/R-induced lung injury. Previous studies have reported that activated neutrophils are an important factor in tissue injury and serve a significant role in the progression of ALI (26–28). Therefore, the results of the present study demonstrated that lung injury was caused by II/R, thus confirming the model reliability.

The present study suggested that TNF-α, either locally produced at the site of ischemia or generated directly from the lung tissue affected by II/R, had important effects on the lungs. The results indicated that TNF-α expression was upregulated in lung tissues, alongside ultrastructural alterations and lung injuries. In addition, the alterations in TNF-α expression levels differed with the time post-reperfusion. In the present study, the expression levels of TNF-α were increased in the lung tissues of the II/R group after 8 h reperfusion and peaked 24 h post-reperfusion. A previous study provided evidence to suggest that in I/R injury, excessive elevation of proinflammatory cytokines is a major contributor in remote organ injury (12). The proinflammatory molecule, TNF-α, can induce direct tissue damage and is also a potent activator of neutrophils (29,30). In a previous study, Sorkine et al revealed that serum TNF concentration peaked 30 min after reperfusion, but returned to baseline values within 180 min (17). In addition, Narita et al reported that plasma TNF-α levels in an II/R group were increased 30 min after the start of ischemia, and fluctuated during I/R (30 min after intestinal reperfusion); however, 180 min after reperfusion, the plasma TNF levels were not significantly increased in the intestinal I/R rats compared with in the sham rats (12). Conversely, the present results indicated that the longer the duration of reperfusion, the higher the levels of TNF-α, this may underlie the reason why more severe lung injury was detected 24 h post-reperfusion. These findings indicated that the mRNA expression levels of TNF-α in lung tissue may be more associated with the degree of lung injury compared with plasma levels prior to 24 h post-reperfusion.

The present study demonstrated that TNF-α lentiviral interference decreased the acute inflammatory response, lung injury and lung edema induced by II/R in rats, and it was indicated that its protective role may involve upregulation of IL-10. Until recently, siRNAs have been considered particularly specific (31,32). However, there is growing evidence to suggest that the technique has limitations with regards to siRNA specificity and long-term effects (14,20), whereas shRNAs maintain longer expression and were therefore used in the present study.

In previous studies, blockade of TNF-α has been reported to improve or prevent inflammation in animal models and in humans for the treatment of disease (33–36). In addition, it has been demonstrated that nanoparticle-mediated TNF-α knockdown in peritoneal macrophages may be used to reduce local and systemic inflammation, thereby presenting a novel therapeutic strategy for arthritis, psoriasis and other skin disorders (22,37). Furthermore, potent RNAi against systemic TNF-α production provides a promising approach for the treatment of hepatic injury and other inflammatory diseases (38).

The treatment for II/R-induced ALI is currently limited. It has previously been reported that remote intestinal ischemic preconditioning may confer cytoprotection in critical organs, including the lungs, by attenuating the release of the proinflammatory cytokines TNF-α and IL-1 (12,39). Furthermore, it has been revealed that applying hydrogen-rich saline, ELR-CXC chemokine inhibitors or heparin-binding EGF-like growth factor attenuates II/R-induced lung injury by inhibiting II/R injury-associated inflammatory events in clinical situations (40–42). However, few studies have focused on the protective effects of TNF-α knockdown, the possible mechanisms underlying II/R-induced ALI and the potential clinical application of TNF-α RNAi in patients with II/R-induced ALI. To the best of our knowledge, the present study is the first to demonstrate the protective effects of TNF-α RNAi on II/R-induced ALI via the upregulation of IL-10 expression (Fig. 6).

Figure 6 Diagram of the underlying mechanism by which TNF-α shRNA serves a protective role in a rat model of II/R-induced ALI. At various time points post-reperfusion, evidence of ALI was detected by hematoxylin and eosin staining. qPCR, WB and IF indicated that the expression levels of TNF-α were significantly increased in the lung tissues. TNF-α shRNA protected lungs from II/R-induced acute injury by upregulating IL-10 expression. The circles above the arrows indicate inhibition. ALI, acute lung injury; IF, immunofluorescence; II/R, intestinal ischemia and reperfusion; IL-10, interleukin-10; qPCR, quantitative polymerase chain reaction; shRNA, short hairpin RNA; TNF-α, tumor necrosis factor-α; WB, western blotting.

In conclusion, the present study demonstrated that TNF-α may be a major contributor in II/R-induced ALI, and TNF-α RNAi may alleviate the severity of ALI. Notably, TNF-α RNAi exerted a protective effect on II/R-induced ALI via upregulation of the anti-inflammatory cytokine IL-10. Based on these findings, TNF-α knockdown may be considered a novel therapeutic strategy for the treatment of II/R-induced ALI.

Acknowledgments

The authors would like to thank Dr Qing-Jie Xia (West China Hospital, Sichuan University, Chengdu, China) for suggestions on this study.

Funding

The present study was supported by a grant from the Key Natural Science Foundation of Yunnan (grant no. 2013FZ264).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

ZY, XRZ, THW and YHZ designed the project and were major contributors in writing and revising the manuscript. QZ and SLW participated in the production of recombinant lentiviral vector. LLX and PZ carried out the II/R model and lentivirus injection. QZ, BY and ZBZ carried out the histological analysis. QZ, SYF, ZY and XRZ carried out the qPCR, IF staining, and western blot analysis. ZY, XRZ, THW and ZYH analyzed the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Animal care and all experimental protocols were approved by the Institutional Medical Experimental Animal Care Committee of Kunming Medical University (Kunming, China).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References